This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06065540 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 2,734 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Type 2 Diabetes Mellitus |
| Interventions | Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide |
| Start | Sep 27, 2023 |
| Primary completion | Nov 19, 2025 |
| Study completion | Jan 6, 2026 |
| Results posted | Not yet |
| Registry last updated | Jul 8, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c) | From baseline (week 0) to end of treatment (week 68) |
37 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
